Delving into the Latest Updates on MPH-220 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

MYH2

Mechanism

MYH2 inhibitors(myosin heavy chain 2 inhibitors)

Therapeutic Areas

Nervous System DiseasesSkin and Musculoskeletal Diseases

Active Indication

Muscle Spasticity

Inactive Indication-

Originator Organization

Motorpharma Ltd.Startup

Active Organization

MyoKardia, Inc.

KAINOMYX, INC.

Cytokinetics, Inc.

+ [1]

Inactive Organization

Motric Bio

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Gyimesi, Máté ; Pál, Endre ; Kovács, Mihály ; Málnási-Csizmadia, András ; Komoly, Sámuel ; Rauscher, Anna Á ; Horváth, Ádám I ; Pénzes, Máté ; Canon, Louise ; Lőrincz, István ; Spudich, James A ; Ruppel, Kathleen M ; Houdusse, Anne ; Trivedi, Darshan V ; Suthar, Sharad Kumar ; Túrós, Demeter ; Kikuti, Carlos ; Kurdi, Csilla

Muscle spasticity after nervous system injuries and painful low back spasm affect more than 10% of global population. Current medications are of limited efficacy and cause neurological and cardiovascular side effects because they target upstream regulators of muscle contraction. Direct myosin inhibition could provide optimal muscle relaxation; however, targeting skeletal myosin is particularly challenging because of its similarity to the cardiac isoform. We identified a key residue difference between these myosin isoforms, located in the communication center of the functional regions, which allowed us to design a selective inhibitor, MPH-220. Mutagenic analysis and the atomic structure of MPH-220-bound skeletal muscle myosin confirmed the mechanism of specificity. Targeting skeletal muscle myosin by MPH-220 enabled muscle relaxation, in human and model systems, without cardiovascular side effects and improved spastic gait disorders after brain injury in a disease model. MPH-220 provides a potential nervous-system-independent option to treat spasticity and muscle stiffness.

100 Deals associated with MPH-220

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Muscle Hypertonia	Phase 2	HU	Motric Bio	15 Nov 2021
Muscle Spasticity	Preclinical	US	KAINOMYX, INC.	01 Oct 2020
Muscle Spasticity	Preclinical	HU	Motorpharma Ltd.Startup	01 Oct 2020
Muscle Spasticity	Preclinical	US	MyoKardia, Inc.	01 Oct 2020
Muscle Spasticity	Preclinical	US	Cytokinetics, Inc.	01 Oct 2020